141 related articles for article (PubMed ID: 35529932)
1. Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines.
Gu J; Ni X; Ji J; Wei G; Shi L; Xu C
Evid Based Complement Alternat Med; 2022; 2022():8060026. PubMed ID: 35529932
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
Wang Z; He T; Yu D; Qin X; Geng A; Yang H
Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17.
Chen R; Chen QT; Dong YH
Oncol Lett; 2019 Jun; 17(6):5447-5452. PubMed ID: 31186764
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer.
Han G; Sun C; Cui L; Huang Y; Yu L; Liu S; Tao M
Pathol Oncol Res; 2023; 29():1611114. PubMed ID: 37465317
[No Abstract] [Full Text] [Related]
7. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
Ouyang T; Cao Y; Chen L; Zheng C
Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
Yan Y; Li H; Wu S; Wang G; Luo H; Niu J; Cao L; Hu X; Xu H; Jia W; Sun Y; Yao Y; Chen W; Ke L; Hu B; Ji C; Sun Y; Chen J; Li M; He Y
Ann Transl Med; 2022 Feb; 10(4):205. PubMed ID: 35280426
[TBL] [Abstract][Full Text] [Related]
9. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Liu H; Li Y; Yao Y; Chen K; Gan J
Dis Markers; 2022; 2022():6971717. PubMed ID: 36193493
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects and safety of apatinib mesylate on patients with gastric carcinoma peritoneal metastasis in SOX scheme.
Wang HF; Wang HH; Ye XJ; Wang WJ; Teng LS
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6627-6638. PubMed ID: 37522674
[TBL] [Abstract][Full Text] [Related]
13. Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.
Pan D; Liu D; Liang L; Shen T; Shi C; Qin H
Front Oncol; 2022; 12():863392. PubMed ID: 35664730
[TBL] [Abstract][Full Text] [Related]
14. Retracted: Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines.
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9787205. PubMed ID: 38125103
[TBL] [Abstract][Full Text] [Related]
15. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
16. Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer.
Cui Q; Mao Y; Wu D; Hu Y; Ma D; Zhang L; Liu H
Front Oncol; 2022; 12():952494. PubMed ID: 36387189
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the Efficacy and Safety of Trastuzumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Yue J; Long Z
Altern Ther Health Med; 2023 Dec; ():. PubMed ID: 38064625
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
20. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].
Ye ZS; Zeng Y; Wei SH; Wang Y; Chen S; Lin ZT; Wang ZW; Chen XL; Chen LC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):240-247. PubMed ID: 34645168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
